Prior to joining the company, Berenson served as president and CEO at HemaQuest Pharmaceuticals and as founder, director, president and CEO at Xcyte Therapies.
He also served as founder, director, executive vice president, chief medical officer and chief scientific officer at CellPro, where he was responsible to include the FDA-approved biological product in cell therapy into the company’s product portfolio.
In the new role, Berenson will further develop the Aequus’ GlycoPolymer technology and expand the business.
GlycoPolymer technology, which is currently under development, is aimed at creating glycoengineered protein-based biotherapeutics with improved pharmacokinetic properties that require less frequent injections than current therapies.
Aequus BioPharma president and CEO Ronald Berenson said patient convenience and compliance continue to be issues with therapeutic proteins due to the need for frequent injections.
"I believe that Aequus’s novel approach could address these challenges with the potential to be applied to a wide spectrum of therapeutics," Berenson added.